A Chinese medicine-based herbal formula developed in Taiwan called Taiwan Chingguan Erhau (清冠二號), or NRICM102, could reduce the mortality rate of COVID-19 cases who experience severe symptoms by 50 percent, National Research Institute of Chinese Medicine (NRICM) director Su Yi-chang (蘇奕彰) said.
Su talked about the treatment on Sunday at the Taipei Traditional Chinese Medicine International Forum, saying that following the success of Taiwan Chingguan Yihau (清冠一號), or NRICM101, the institute is applying for patents and trademarks for the new formulation.
In 2020, permission was granted to export Taiwan Chingguan Yihau, and it has been sold in more than 50 countries with positive responses from overseas, Su said.
Photo: Tsai Si-pei, Taipei Times
Taiwan Chingguan Yihau received emergency use authorization in May last year from the Ministry of Health and Welfare, which allowed it to be manufactured and used for clinical treatment in Taiwan.
Eight pharmaceutical companies have authorization to manufacture the formula.
Taiwan Chingguan Erhau is a modification of its predecessor, which includes indigowoad root, heartleaf houttuynia herb and scutellaria root, among others, Su said.
Ingredients “helpful in fighting viruses” and “regulating the immune system” remain in Taiwan Chingguan Erhau, while stronger substances that “help bolster health maintenance” were substituted for those with modest effects, he added.
Clinical trials of Taiwan Chingguan Yihau were conducted from May to August last year in 15 hospitals including the Tri-Service General Hospital, Taipei Hospital and Taoyuan General Hospital.
Results showed that the chance of people with COVID-19 developing severe symptoms was reduced by 80 percent if they were using the formula, Su said.
Over the same period, more than 100 cases with severe symptoms received Taiwan Chingguan Erhau in clinical trials, with results suggesting a 50 percent drop in mortality rate within 30 days, he said.
Asking pharmaceutical companies to target only COVID-19 cases with severe symptoms is impractical as the pandemic wanes, Su said, adding that the institute plans to test Taiwan Chingguan Erhau’s usefulness against other severe lung diseases.
The formula’s effectiveness in treating chronic obstructive pulmonary disease, cardiac and pulmonary arrest, and pulmonary embolism are being assessed, he said.
Su also said that unlike Western medicines that target one disease, a Chinese medical formula can usually treat many diseases.
Taking Chinese medicine is unlikely to produce side effects or develop resistance the same way drugs or antibiotics do, he said.
Su said that the institute plans to approach companies that are interested in manufacturing Taiwan Chingguan Erhau and follow the procedures for launching new medical treatments in Taiwan.
ANOTHER EMERGES: The CWA yesterday said this year’s fourth storm of the typhoon season had formed in the South China Sea, but was not expected to affect Taiwan Tropical Storm Gaemi has intensified slightly as it heads toward Taiwan, where it is expected to affect the country in the coming days, the Central Weather Administration (CWA) said yesterday. As of 8am yesterday, the 120km-radius storm was 800km southeast of Oluanpi (鵝鑾鼻), Taiwan’s southernmost tip, moving at 9kph northwest, the agency said. A sea warning for Gaemi could be issued tonight at the earliest, it said, adding that the storm is projected to be closest to Taiwan on Wednesday or Thursday. Gaemi’s potential effect on Taiwan remains unclear, as that would depend on its direction, radius and intensity, forecasters said. Former Weather Forecast
As COVID-19 cases in Japan have been increasing for 10 consecutive weeks, people should get vaccinated before visiting the nation, the Centers for Disease Control (CDC) said. The centers reported 773 hospitalizations and 124 deaths related to COVID-19 in Taiwan last week. CDC Epidemic Intelligence Center Director Guo Hung-wei (郭宏偉) on Tuesday said the number of weekly COVID-19 cases reported in Japan has been increasing since mid-May and surpassed 55,000 cases from July 8 to July 14. The average number of COVID-19 patients at Japan’s healthcare facilities that week was also 1.39 times that of the week before and KP.3 is the dominant
The Chinese Communist Party’s (CCP) working group for Taiwan-related policies is likely to be upgraded to a committee-level body, a report commissioned by the Mainland Affairs Council (MAC) said. As Chinese President Xi Jinping (習近平) is increasingly likely to upgrade the CCP’s Central Leading Group for Taiwan Affairs, Taiwanese authorities should prepare by researching Xi and the CCP, the report said. At the third plenary session of the 20th Central Committee of the CCP, which ended on Thursday last week, the party set a target of 2029 for the completion of some tasks, meaning that Xi is likely preparing to
US-CHINA TRADE DISPUTE: Despite Beijing’s offer of preferential treatment, the lure of China has dimmed as Taiwanese and international investors move out Japan and the US have become the favored destinations for Taiwanese graduates as China’s attraction has waned over the years, the Ministry of Labor said. According to the ministry’s latest income and employment advisory published this month, 3,215 Taiwanese university graduates from the class of 2020 went to Japan, surpassing for the first time the 2,881 graduates who went to China. A total of 2,300 graduates from the class of 2021 went to the US, compared with the 2,262 who went to China, the document showed. The trend continued for the class of 2023, of whom 1,460 went to Japan, 1,334 went to